Consequently, considering the results observed in the golden hamster model, IVM may be considered as a therapeutic agent against COVID‐19, which would not strongly affect SARS‐CoV‐2 replication but limit the pathophysiological consequences of the infection in vivo, potentially mediated by type I and III IFN responses and several other related signaling pathways, and a favorable M1/M2 myleoid cells ratio in the lungs. This evidence concerns the gene IFNA1 and infection.